Abstract Library

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

#2806 Sarcopenia: Don't Judge a Book by It's Cover

Introduction: Sarcopenia is characterised by loss of muscle mass and function. We previously reported anthropometrical data for a range of NET diagnoses within 3 months of diagnosis. The majority of NET patients were overweight or obese, however reduced muscle function was observed in over half of patients regardless of BMI and other parameters.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Whyand T, Chotai de Lima Y, Caplin M,

Keywords: Neuroendocrine neoplasm, nutrition, dietitian, sarcopenia,

#2195 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs)

Introduction: The number of people living with cancer in the UK continues to rise with increased demands on specialist cancer care services. NET incidence and prevalence increases alongside this demand. NETs remain a rare cancer with specialist needs. The clinical nurse specialist (CNS) is ideally placed to support these patients. Oncology clinics are increasingly pressured, the need to think of innovative ways of reducing strain whilst maintaining and enhancing the patients experience is important. To address this we set up a nurse-led SACT NMP clinic alongside the oncology clinic to improve patient experience and reduce oncologist clinic review.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davies P

Authors: Davies P, Quaglia E, McSweeney A, Caplin M, Thirlwell C,

Keywords: Nurse, Non-Medical Prescribing, SACTs, neuroendocrine, chemotherapy, everolimus, sunitinib,

#2187 Typical and Atypical Bronchial NETs with Advanced Disease: Incidence, Management and Survival

Introduction: Bronchial NETs are classified according to the 2004 WHO classification into typical, atypical and poorly differentiated. Typical and atypical tumours can develop metastatic disease (Stage IV) which requires careful management

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: McFadyen R

Authors: McFadyen R, Smith J, Diamantopoulos L, Caplin M, Toumpanakis C,

Keywords: typical, atypical, bronchial, ki-67,

#2129 Phosphohistone H3 (PHH3) Immunohistochemical Staining Outperforms Conventional H&E Mitotic Count in Classifying Pulmonary Carcinoids

Introduction: Pulmonary carcinoids (PC) are well-differentiated NETs and are classified as typical carcinoid (TC) and atypical carcinoid (AC). Despite the fact that TC and AC exhibit significant differences in patient survival, their classification depends on relatively subtle differences in mitotic count (MC). Although careful counting of mitotic figures (MF) is essential, it is a very subjective task, time-consuming and lacks of sensitivity and interobserver reproducibility, due to selection bias of the hot spots, heterogeneous distribution of MF, difficulty in distinguishing MF from similar chromatin changes (i.e. in apoptotic cells or due to crush, karyorrhectic debris, pyknosis or apoptosis).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Luong T

Authors: Luong T, McCaughran W, Caplin M, Toumpanakis C, Thirlwell C,

Keywords: Phosphohistone H3, Pulmonary Carcinoids, Typical Carcinoid, Atypical Carcinoid, Mitotic Count, H&E,